A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of VRG50635 in Healthy Volunteers
Latest Information Update: 19 Dec 2024
At a glance
- Drugs VRG-50635 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Verge Genomics
Most Recent Events
- 12 Dec 2024 Status changed from recruiting to completed.
- 25 Mar 2024 Status changed from not yet recruiting to recruiting.
- 05 Mar 2024 New trial record